ClinicalTrials.gg
Not yet recruitingNCT07941440PRXS-SINGLEUpdated Nov 17, 2026

Clinical Outcomes of PRX S With Standardized Home Care in Mild-to-Moderate Facial Acne.

An interventional study of PRX S Facial Treatment and Standardized Home Skin Care in Acne Vulgaris, sponsored by Medical University of Silesia. Not yet recruiting at 2 sites in Poland. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Medical University of Silesia · Not applicable, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Acne Vulgaris with a site in Poland — 1 open to participants now, 5 under way, 1 of them phase 3. Acne Vulgaris · Poland.

Planned enrollment
17th of 18
30 · median 364
Started
2026
with 1 other
No phase
5 of 24
1 open now
Registered
24th of 24
by date
Lead sponsor
1 of 24
Medical University of Silesia

Among the 24 studies in Acne Vulgaris with a site in Poland, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 24th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 24 studies in Acne Vulgaris with a site in Poland is open now.

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Acne Vulgaris with a site in Poland, or all of them as a file.
02

Study summary

This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.

The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.

The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.

Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.

All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.

Read the detailed description

This study aims to assess changes in facial acne lesions and skin condition following a series of five PRX S treatments combined with standardized home skin care in adults with mild-to-moderate acne.

The study will include 30 adults aged 18-60 years with mild-to-moderate facial acne. All participants will receive five PRX S treatments at two-week intervals and use the same home-care products, including a nourishing cream and an active Balancing Cream.

The main objective is to determine how the number of inflammatory acne lesions (papules and pustules) changes from the beginning of the study to two weeks after the fifth treatment. The study will also assess other acne lesions, overall acne severity, skin oiliness, hydration, elasticity, skin surface characteristics, and skin thickness using clinical examinations and specialized instruments. Skin tolerability and any adverse events will also be monitored.

Participants will undergo assessments before treatment, after three completed treatments, two weeks after the fifth treatment, and approximately two months later.

All participants will receive the same treatment regimen. There will be no placebo or untreated comparison group. Therefore, the study will describe changes observed during the combined treatment program but will not determine the separate effects of PRX S or establish its superiority over other treatments.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Mild-to-moderate facial acne
  • Inflammatory acne lesions
  • PRX S
  • Topical skin treatment
  • Standardized home skin care
  • Skin sebum
  • Skin hydration
  • Skin elasticity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-60 years.
  • Mild-to-moderate facial acne vulgaris, defined as Investigator's Global Assessment (IGA) grade 2 or 3, confirmed by a dermatologist at baseline (T0).
  • Presence of at least five inflammatory facial acne lesions (papules and/or pustules) at baseline.
  • Provision of written to participate in the study and undergo study-related assessments and documentation.
  • No to the study products and confirmation by a dermatologist that the treatment regimen is clinically appropriate.
  • Ability and willingness to attend scheduled study visits and comply with the standardized home skin-care regimen.
  • No urgent need for alternative acne treatment that is not provided within the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Investigator's Global Assessment (IGA) grade 0, 1, or 4.
  • Severe or nodulocystic acne, deep inflammatory lesions, or rapidly progressive acne scarring requiring alternative medical management.
  • Pregnancy or breastfeeding.
  • Known to any component of the study products.
  • Active herpes simplex infection, other skin infections, wounds, erosions, or burns in the treatment area.
  • Active atopic dermatitis, seborrheic dermatitis, or other skin conditions that may interfere with study assessments.
  • Skin or suspicious lesions in the treatment area.
  • Medical conditions or concurrent therapies that may significantly increase treatment-related risks or interfere with the interpretation of study outcomes.
  • Use of topical retinoids within 30 days before baseline (T0).
  • Completion of anti-acne antibiotic therapy less than 3 months before baseline (T0).
  • Completion of isotretinoin therapy less than 6 months before baseline (T0).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    PRX S Treatment Combined With Standardized Home Care

    Participants will receive five professional PRX S facial treatments at approximately 14-day intervals (days 0, 14, 28, 42, and 56), combined with standardized home skin care consisting of WIQO Nourishing Cream for Normal and Combination Skin applied in the morning and WIQO Balancing Cream applied in the evening. Home care will continue throughout the study, including the follow-up period. Clinical and instrumental assessments will be performed at baseline (T0), after three completed treatments (T1), two weeks after the fifth treatment (T2), and two calendar months after T2 (T3). All participants will receive the same combined regimen, with no placebo or comparator group.

    Procedure: PRX S Facial Treatment · Other: Standardized Home Skin Care

Interventions

  • ProcedurePRX S Facial Treatment

    PRX S is a two-phase topical preparation activated immediately before professional application according to the manufacturer's instructions for use. Participants will undergo five facial treatment sessions at approximately 14-day intervals (days 0, 14, 28, 42, and 56). The procedure will be performed using a standardized protocol appropriate for mild-to-moderate facial acne. The application technique, treatment quantity, and number of layers will follow the approved standard operating procedure and current manufacturer's instructions.

  • OtherStandardized Home Skin Care

    All participants will follow a standardized home skin-care regimen using WIQO Nourishing Cream for Normal and Combination Skin and WIQO Balancing Cream. The nourishing cream will be used in the morning and the Balancing Cream in the evening according to the approved study instructions. Home care will continue throughout the treatment and follow-up periods. The regimen will be identical for all participants.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 70

    The outcome is the within-participant change in the total number of inflammatory facial acne lesions (papules and pustules) between baseline (T0) and T2. Lesions will be counted by a trained dermatologist using a standardized facial lesion-counting procedure. The change will be calculated as the T2 lesion count minus the baseline lesion count. A negative value indicates a reduction in inflammatory lesions.

    Time frame: Baseline (Day 0) and Day 70 (14 days after the fifth treatment)

Secondary outcomes

  1. Change From Baseline in Inflammatory Facial Acne Lesion Count at Day 42

    Change in the total number of facial inflammatory acne lesions (papules and pustules), counted by a trained dermatologist. The change is calculated as the Day 42 count minus the baseline count. Negative values indicate improvement.

    Time frame: Baseline (Day 0) and Day 42 (after three completed treatments, before the fourth treatment).

  2. Change From Baseline in Inflammatory Facial Acne Lesion Count at Follow-up

    Change in the total number of facial inflammatory acne lesions (papules and pustules) between baseline and T3, assessed by a trained dermatologist using standardized lesion counting. Negative values indicate a reduction in inflammatory lesions.

    Time frame: Baseline (Day 0) and T3 (two calendar months after Day 70).

  3. Change From Baseline in Facial Comedone Count

    Change in the total number of non-inflammatory facial acne lesions, including open and closed comedones, assessed by a trained dermatologist using standardized lesion counting. The change at each post-baseline visit is calculated as the visit count minus the baseline count. Negative values indicate fewer comedones.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  4. Percentage Reduction From Baseline in Inflammatory Facial Acne Lesion Count

    Percentage reduction in the total number of facial inflammatory acne lesions (papules and pustules), calculated as 100 × (baseline lesion count - post-baseline lesion count) / baseline lesion count. Positive values indicate a reduction in inflammatory lesions. Participants are required to have at least five inflammatory lesions at baseline.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  5. Change in Investigator's Global Assessment of Acne Severity

    Acne severity will be assessed by a dermatologist using the static Investigator's Global Assessment (IGA) scale ranging from 0 (clear) to 4 (severe). The distribution of IGA grades and changes in grades from baseline will be reported at each assessment visit. Lower grades indicate less severe acne.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  6. Percentage of Participants Achieving an Investigator's Global Assessment Grade of 0 or 1

    Percentage of evaluable participants achieving an Investigator's Global Assessment (IGA) grade of 0 (clear) or 1 (almost clear) at each post-baseline assessment. IGA is a five-category ordinal scale ranging from 0 (clear) to 4 (severe).

    Time frame: Day 42, Day 70, and T3 (two calendar months after Day 70).

  7. Percentage of Participants Achieving Investigator's Global Assessment Success

    IGA success is defined as achieving an Investigator's Global Assessment grade of 0 (clear) or 1 (almost clear), together with an improvement of at least two grades from baseline. Participants with baseline IGA 2 must achieve grade 0, while participants with baseline IGA 3 may achieve grade 0 or 1.

    Time frame: Day 42, Day 70, and T3 (two calendar months after Day 70).

  8. Change From Baseline in Facial Skin Sebum Level Measured by Sebumetry

    Facial skin surface sebum will be measured using a sebumeter under standardized measurement conditions. Results will be expressed in micrograms per square centimeter (µg/cm²). Changes from baseline will be calculated at each post-baseline assessment.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  9. Change From Baseline in Stratum Corneum Hydration Measured by Corneometry

    Skin hydration will be assessed using corneometry under standardized measurement conditions. Measurements reflect hydration of the stratum corneum and are expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  10. Change From Baseline in Skin Elasticity (Cutometer R2 Parameter)

    Skin biomechanical properties will be assessed using a Cutometer. The R2 parameter, representing gross skin elasticity, will be recorded as a dimensionless ratio. Changes from baseline will be calculated at each post-baseline assessment.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  11. Change From Baseline in Dermal Thickness Measured by Skin Ultrasonography

    Dermal thickness will be measured using skin ultrasonography at standardized anatomical measurement sites. Results will be expressed in millimeters (mm). Changes from baseline will be calculated at each post-baseline assessment.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  12. Change From Baseline in Dermal Echogenicity Measured by Skin Ultrasonography

    Dermal echogenicity will be assessed using skin ultrasonography under standardized acquisition conditions. Results will be expressed in instrument-specific arbitrary units. Changes from baseline will be calculated at each post-baseline assessment.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

  13. Change From Baseline in Facial Skin Surface Parameters Assessed by Antera 3D

    Changes in facial skin surface characteristics, including pore-related parameters, skin texture, and surface roughness, will be assessed using the Antera 3D imaging system. Measurements will be performed at standardized anatomical sites and compared with baseline values.

    Time frame: Baseline (Day 0), Day 42, Day 70, and T3 (two calendar months after Day 70).

07

Study locations

2 sites
  • AJ Med
    Mysłowice, 41-400, Poland
  • Department of Practical Cosmetology and Skin Diagnostics
    Sosnowiec, 41-208, Poland
08

References and documents

Publications

  • Messaraa C, Metois A, Walsh M, Hurley S, Doyle L, Mansfield A, O'Connor C, Mavon A. Wrinkle and roughness measurement by the Antera 3D and its application for evaluation of cosmetic products. Skin Res Technol. 2018 Aug;24(3):359-366. doi: 10.1111/srt.12436. Epub 2018 Jan 24. PubMed 29368349 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the reported study results may be made available to qualified researchers upon reasonable request, subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Data sharing will be considered on a case-by-case basis.

Supporting information: Study protocol, Statistical analysis plan

Time frame: De-identified individual participant data may be made available upon reasonable request following publication of the main study results, subject to participant consent, applicable data protection requirements, and sponsor authorization. The duration of availability will be determined in accordance with the sponsor's data retention and sharing policies.

Access criteria: De-identified individual participant data underlying the published study results may be made available to qualified researchers upon reasonable request. Requests will be reviewed on a case-by-case basis and will be subject to participant consent, applicable data protection requirements, and authorization by the study sponsor. Access will be limited to data approved for sharing. Participant-identifiable information and identifiable facial photographs will not be shared without the appropriate consent and legal basis.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2027, 3 months later.

Of 58 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 17. This study's planned 3 months is below that.

Counting every sponsor, half of 120 studies reached it within 9 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
May 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07941440
Collaborators
WiQo S.p.A.
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Mar 30, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Anna Deda, PhD
Contact
adeda@sum.edu.pl
+48 500 233 457
Anna Deda, PhD
principal investigator · Medical University of Silesia in Katowice, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion